WO2007100904A3 - Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof - Google Patents

Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof Download PDF

Info

Publication number
WO2007100904A3
WO2007100904A3 PCT/US2007/005380 US2007005380W WO2007100904A3 WO 2007100904 A3 WO2007100904 A3 WO 2007100904A3 US 2007005380 W US2007005380 W US 2007005380W WO 2007100904 A3 WO2007100904 A3 WO 2007100904A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugate
tumor
production
anticancer agents
tumor vasculature
Prior art date
Application number
PCT/US2007/005380
Other languages
French (fr)
Other versions
WO2007100904A2 (en
Inventor
Roger G Harrison
Thomas J Pento
Stuart E Lind
Original Assignee
Regent Of The University Of Ok
Roger G Harrison
Thomas J Pento
Stuart E Lind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regent Of The University Of Ok, Roger G Harrison, Thomas J Pento, Stuart E Lind filed Critical Regent Of The University Of Ok
Publication of WO2007100904A2 publication Critical patent/WO2007100904A2/en
Publication of WO2007100904A3 publication Critical patent/WO2007100904A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A conjugate is disclosed herein, wherein the conjugate includes a ligand having the ability to specifically and stably bind to an external receptor or binding site on a tumor vasculature endothelial cell, wherein the external receptor or binding site is specific for tumor vasculature endothelial cells. The conjugate also includes an anticancer agent that is selectively toxic to cancer cells operatively attached to the ligand. The anticancer agent may be L-methioninase. Pharmaceutical compositions comprising the conjugate are also disclosed, as well as methods of treating a cancer tumor or cancer cells with a therapeutically effective amount of the conjugate.
PCT/US2007/005380 2006-02-28 2007-02-28 Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof WO2007100904A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77772506P 2006-02-28 2006-02-28
US60/777,725 2006-02-28

Publications (2)

Publication Number Publication Date
WO2007100904A2 WO2007100904A2 (en) 2007-09-07
WO2007100904A3 true WO2007100904A3 (en) 2008-11-13

Family

ID=38459680

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/005380 WO2007100904A2 (en) 2006-02-28 2007-02-28 Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof

Country Status (1)

Country Link
WO (1) WO2007100904A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8231895B2 (en) 2008-05-22 2012-07-31 Universidade De Coimbra Targeted delivery to human diseases and disorders
EP3292140B1 (en) * 2015-05-05 2022-04-20 Rubicon Biotechnology LLC Cancer immunotherapeutic

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050036984A1 (en) * 2003-06-17 2005-02-17 Harrison Roger G. Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050036984A1 (en) * 2003-06-17 2005-02-17 Harrison Roger G. Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof

Also Published As

Publication number Publication date
WO2007100904A2 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
WO2008103470A3 (en) Oncogenic-ras-signal dependent lethal compounds
WO2007112193A3 (en) Camptothecin-binding moiety conjugates
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
UA95959C2 (en) Leptomycin derivatives
WO2008115262A3 (en) Hsp90 inhibitors containing a zinc binding moiety
WO2009002808A3 (en) Quinazolinone compounds and methods of use thereof
WO2009016516A8 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
IL208937A0 (en) Cell binding agent cytotoxic drug conjugates, compositions comprising the same and uses thereof
WO2006113623A3 (en) Elimination of heterogeneous or mixed cell population in tumors
WO2008089397A3 (en) Adrb2 cancer markers
WO2006061258A3 (en) Cytotoxic agents comprising new taxanes
NZ599045A (en) New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
EP2952210A3 (en) Compositions comprising saccharide binding moieties and methods for targeted therapy
WO2007120648A3 (en) Mono and di-substituted oxycodone compounds and compositions
WO2008082602A3 (en) Compounds and pharmaceutical compositions for the treatment of liver disorders
WO2008058239A3 (en) Spink1 as a prostate cancer marker and uses thereof
WO2007009191A8 (en) Method for treating cancer
WO2008086269A3 (en) 6-aminoisoquinoline compounds useful as kinase modulators
WO2006137009A3 (en) Fluorescent sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as therapeutic and diagnostic agents
WO2007008539A3 (en) Pyranopyridine compounds
WO2009018122A3 (en) Methods and compositions for increasing alpha-iduronidase activity in the cns
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
WO2010087976A3 (en) Anti-cancer protein-platinum conjugates
WO2011054837A3 (en) Bifunctional prodrugs and drugs
WO2008002460A3 (en) Orally available light-independent antineoplastic compounds

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07752103

Country of ref document: EP

Kind code of ref document: A2